Baran, Amprose .

HRN: 14-13-84  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/09/2024
CEFUROXIME 500MG (TAB)
01/09/2024
01/16/2024
ORAL
500mg
BID
NSVD With Right Mediolateral Episiorrhapy
Checking Final Appropriateness 

Indication:  ProphylaxisEmpiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Intervention



Type of Intervention done:

                    

           


Acceptance: